TY - JOUR
T1 - Clinical value of whole-body FDG-PET for recurrent gastric cancer
T2 - A multicenter study
AU - Nakamoto, Yuji
AU - Togashi, Kaori
AU - Kaneta, Tomohiro
AU - Fukuda, Hiroshi
AU - Nakajima, Kotaro
AU - Kitajima, Kazuhiro
AU - Murakami, Koji
AU - Fujii, Hirofumi
AU - Satake, Mitsuo
AU - Tateishi, Ukihide
AU - Kubota, Kazuo
AU - Senda, Michio
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for Cancer Research (17-12) from the Ministry of Health, Labour and Welfare, Tokyo, Japan.
PY - 2009
Y1 - 2009
N2 - Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.
AB - Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.
KW - 18F-FDG
KW - Gastric cancer
KW - PET
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=65549094936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65549094936&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyp010
DO - 10.1093/jjco/hyp010
M3 - Article
C2 - 19269991
AN - SCOPUS:65549094936
VL - 39
SP - 297
EP - 302
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 5
ER -
